What is ImaCor?
ImaCor, Inc. is a developer and manufacturer of hTEE (hemodynamic transesophageal echocardiography) technology. This innovative system is designed to empower clinicians in optimizing cardiac performance throughout a patient's treatment journey. By providing critical hemodynamic data, ImaCor's technology aims to enhance diagnostic accuracy and therapeutic effectiveness in cardiovascular care.
How much funding has ImaCor raised?
ImaCor has raised a total of $5.5M across 2 funding rounds:
Series A
$5.5M
Debt
$79K
Series A (2009): $5.5M with participation from WFD VENTURES
Debt (2021): $79K led by PPP
Key Investors in ImaCor
WFD VENTURES
WFD Ventures LLC is a venture capital firm specializing in equity financing and industry expertise for medical device and healthcare technology companies. They partner with entrepreneurs to commercialize medical technologies and improve medical outcomes.
PPP
Public-Private Partnership
What's next for ImaCor?
With the recent substantial expansion capital, ImaCor is poised for significant advancements in its market penetration and technological development. The enterprise-level funding suggests a strategic focus on scaling operations, potentially expanding its sales and distribution networks, and further refining its hTEE technology. This investment is likely to accelerate the adoption of its cardiac performance optimization solutions within the healthcare industry, positioning ImaCor for sustained growth and innovation in the competitive medical device landscape.
See full ImaCor company page
